ARXS

Arxis, Inc. Class A Common Stock
NASDAQINDUSTRIALSAEROSPACE & DEFENSE

Key Statistics

Market Cap
$17.58B
P/E Ratio
2142.00
EPS
$0.02
Beta
52W High
$48.68
52W Low
$33.15
50-Day MA
$39.70
200-Day MA
$39.48
Dividend Yield
Profit Margin
6.21%
Forward P/E
59.88
PEG Ratio

About Arxis, Inc. Class A Common Stock

Arxis, Inc. (ARXS) is a leading biotechnology firm dedicated to pioneering advanced therapeutics for complex diseases. The company has a strong focus on research and development, channeling resources into its innovative drug pipeline that addresses both rare and widespread medical conditions. By fostering collaborative partnerships and engaging in robust clinical programs, Arxis is committed to enhancing patient outcomes. As it advances through various clinical trial phases, Arxis is strategically positioned for significant growth, presenting compelling value creation opportunities for institutional investors in the evolving biotech landscape.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$1.67B
Gross Profit (TTM)$827.39M
EBITDA$533.53M
Operating Margin24.20%
Return on Equity1.51%
Return on Assets2.89%
Revenue/Share (TTM)$4.07
Book Value$7.76
Price-to-Book5.80
Price-to-Sales (TTM)10.53
EV/Revenue12.46
EV/EBITDA56.86
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)20.70%
Shares Outstanding$69.66M
Float$66.81M
% Insiders4.03%
% Institutions21.56%

Historical Volatility

HV 10-Day
HV 20-Day
HV 30-Day
HV 60-Day
HV Rank

Analyst Ratings

Consensus ($52.70 target)
1
Strong Buy
9
Buy
1
Hold

Latest News

Arxis Announces Acquisitions of Omnetics Connector Corporation and MagCanica Inc.

BLOOMFIELD, Conn., June 2, 2026 /PRNewswire/ -- Arxis, Inc. (NASDAQ: ARXS) (the "Company" or "Arxis"), a publicly-traded industrial compounder formed in partnership with Arcline Investment Management ("Arcline"), today announced it has entered into a definitive agreement to acquire Omnetics Connector Corporation ("Omnetics"), a leading designer and manufacturer of proprietary high-reliability Micro-D-Sub and Nano-D-Sub connectors and interconnect assemblies used in critical defense and space, commercial aerospace, and medical applications.

PRNewsWire6/2/2026Neutral
Arxis Q1 Earnings Call Highlights

Arxis NASDAQ: ARXS reported a strong first quarter in its first earnings call as a public company, with management pointing to broad-based growth across defense and space, commercial aerospace and industrial technology, as well as a strengthened balance sheet following its initial public offering.

MarketBeat5/28/2026Neutral
Arxis: Critical (Aerospace) Provider Flies Off

Arxis surged 39% on its IPO debut, reflecting strong investor appetite for its roll-up strategy in mission-critical aerospace components. ARXS now trades at a $17 billion valuation, equating to 10x sales and EBITDA multiples in the thirties, despite not matching peer margins. The business model mirrors TransDigm and Loar, leveraging acquisitions, pricing power, and operational efficiencies to drive growth and premium multiples.

Seeking Alpha4/17/2026Positive
Arcline-Backed Arxis Announces Pricing of its Initial Public Offering

BLOOMFIELD, Conn., April 15, 2026 /PRNewswire/ -- Arxis, Inc. ("Arxis"), a portfolio company of Arcline Investment Management and a leading designer and manufacturer of proprietary, mission-critical electronic and mechanical engineered components, announced today the pricing of its upsized initial public offering of 40,500,000 shares of Class A common stock (the "Shares"), offered by Arxis at a public offering price of $28.00 per share.

PRNewsWire4/16/2026Neutral

More INDUSTRIALS Stocks

Data last updated: 7/9/2026